Cyxone Ab Stock Current Asset
CYXO Stock | SEK 0.03 0.01 21.57% |
Cyxone AB fundamentals help investors to digest information that contributes to Cyxone AB's financial success or failures. It also enables traders to predict the movement of Cyxone Stock. The fundamental analysis module provides a way to measure Cyxone AB's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyxone AB stock.
Cyxone |
Cyxone AB Company Current Asset Analysis
Cyxone AB's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
Competition |
In accordance with the recently published financial statements, Cyxone AB has a Current Asset of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current asset for all Sweden stocks is 100.0% higher than that of the company.
Did you try this?
Run Transaction History Now
Transaction HistoryView history of all your transactions and understand their impact on performance |
All Next | Launch Module |
Cyxone Fundamentals
Return On Equity | -1.07 | |||
Return On Asset | -0.59 | |||
Current Valuation | 7.74 M | |||
Shares Outstanding | 98.44 M | |||
Shares Owned By Insiders | 25.38 % | |||
Price To Book | 1.00 X | |||
Price To Sales | 5,168 X | |||
EBITDA | (43.23 M) | |||
Net Income | (45.03 M) | |||
Cash And Equivalents | 56.34 M | |||
Cash Per Share | 0.97 X | |||
Current Ratio | 11.35 X | |||
Book Value Per Share | 0.50 X | |||
Cash Flow From Operations | (43.25 M) | |||
Earnings Per Share | (0.76) X | |||
Target Price | 4.2 | |||
Beta | 0.54 | |||
Market Capitalization | 52.96 M | |||
Total Asset | 46.13 M | |||
Net Asset | 46.13 M |
About Cyxone AB Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyxone AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyxone AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyxone AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cyxone Stock Analysis
When running Cyxone AB's price analysis, check to measure Cyxone AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyxone AB is operating at the current time. Most of Cyxone AB's value examination focuses on studying past and present price action to predict the probability of Cyxone AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyxone AB's price. Additionally, you may evaluate how the addition of Cyxone AB to your portfolios can decrease your overall portfolio volatility.